Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Reported annual fiscal-period values; no daily interpolation.
PEG RATIO
N/A
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
0.12
PEG RATIO AVG 5Y
0.12
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$23.86B
PEG Ratio
33.99
TTM Avg
33.99
3Y Avg
32.78
5Y Avg
16.88
Market Cap
$25.74B
PEG Ratio
1.43
TTM Avg
4.21
3Y Avg
4.21
5Y Avg
2.20
Market Cap
$26.23B
PEG Ratio
8.96
TTM Avg
5.67
3Y Avg
4.53
5Y Avg
3.90
Market Cap
$21.09B
PEG Ratio
1.16
TTM Avg
0.84
3Y Avg
0.59
5Y Avg
0.59
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $24.44B | N/A | N/A | 0.12 | 0.12 |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.86B | 33.99 | 33.99 | 32.78 | 16.88 |
| Incyte Corporation (INCY)vs › | $25.29B | 0.75 | 0.00 | 0.16 | 0.24 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.74B | 1.43 | 4.21 | 4.21 | 2.20 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.23B | 8.96 | 5.67 | 4.53 | 3.90 |
| Labcorp Holdings Inc. (LH)vs › | $26.31B | 1.28 | 0.79 | 0.79 | 0.47 |
| STERIS plc (STE)vs › | $21.14B | 1.03 | 0.80 | 0.61 | 0.61 |
| United Therapeutics Corporation (UTHR)vs › | $21.09B | 1.16 | 0.84 | 0.59 | 0.59 |
| Medline Inc. (MDLN)vs › | $29.52B | N/A | 0.07 | 0.07 | 0.07 |
| Viatris Inc. (VTRS)vs › | $19.28B | N/A | 0.02 | 1.20 | 0.80 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.23 |
| 2021-12-31 | 0.00 |
| 2018-12-31 | 1.32 |
